This article summarizes a bullish thesis on Hormel Foods Corporation (HRL), highlighting its undervaluation based on dividend yield theory. HRL, a leading packaged food company with strong brands, operates in resilient categories, providing stable cash flows and pricing power. Despite recent slower dividend growth, the company's long-term dividend profile, strong balance sheet, and defensive product portfolio suggest potential for margin recovery, earnings growth, and capital appreciation for dividend-oriented investors.

This article analyzes Keurig Dr Pepper Inc. (KDP) as a potential investment, highlighting a bullish thesis from Quality At A Fair Price’s Substack. The investment rationale centers on KDP's attractive valuation, resilient consumer staples positioning, and compelling dividend yield of approximately 3.5%, suggesting the stock may be undervalued. KDP's diverse portfolio across hot and cold beverages, strong brand recognition, and consistent dividend growth further solidify its position as an attractive long-term investment opportunity.

The Gross Law Firm is notifying shareholders of FS KKR Capital Corp (NYSE: FSK) about a securities class action lawsuit. Investors who purchased FSK shares between May 8, 2024, and February 25, 2026, are encouraged to contact the firm regarding potential lead plaintiff appointment. The lawsuit alleges that the company made materially false and/or misleading statements concerning its portfolio restructuring, valuation, and distribution strategy.

Newmont Corporation has acquired a 13.32% stake in LunR Royalties Corp. by receiving 16,099,564 common shares as a dividend-in-kind from Lundin Gold Inc. This strategic move, which involved no cash payment from Newmont, aligns with its investment objectives and high shareholder yield strategy. Newmont stated the shares are held for investment purposes and the company may adjust its holdings in the future.

Bragar Eagel & Squire, P.C. has announced that a class action lawsuit has been filed against Zoetis, Inc. (NYSE:ZTS) on behalf of investors who purchased securities between January 14, 2025, and May 6, 2026. The lawsuit alleges that Zoetis made misleading statements and failed to disclose issues regarding weakening prescription growth for its canine pain treatment Librela, loss of market share for Simparica Trio, and substantial market share loss for its dermatology products due to competing treatments. Investors who suffered losses are encouraged to contact the firm before the July 27, 2026 deadline to apply for lead plaintiff.

HCA Healthcare's Mountain Division, which includes West Valley Medical Center and Eastern Idaho Regional Medical Center, has been named one of the nation’s 15 Top Health Systems by Modern Healthcare for the fourth consecutive year. This recognition is based on an objective quantification of clinical outcomes, operational efficiency, and patient experience, with the Mountain Division being one of only three systems to consistently make the list. The study highlighted the top performers' significant achievements in lower inpatient mortality and fewer healthcare-associated infections.

Sun Gir CEO Harshad Dharod is closing 10 Carl's Jr. locations and selling 49 others in California, citing California's $20 minimum wage and a lack of support from Carl's Jr. as reasons for the company's Chapter 11 bankruptcy filing. Dharod, who operates 65 Carl's Jr. franchises, claims to be losing over $600,000 per month despite generating over $6 million in monthly revenue. The impacted stores, mostly in Los Angeles County, are expected to be sold by the end of summer.

Gelteq (ASX:GELS) has successfully completed veterinary palatability trials with Kemin Industries, validating its gel-based delivery platform for animal health. The trials demonstrated strong canine acceptance and effective masking of bitter flavors, confirming the technology's potential for veterinary pharmaceutical applications. These results are expected to strengthen Gelteq's position for strategic partnerships within the animal health sector.

Gelteq Limited successfully completed veterinary palatability trials with Kemin Industries, validating its proprietary gel-based delivery platform for animal health applications. The trials demonstrated strong canine acceptance and the technology's ability to mask bitter flavors, which is crucial for developing animal therapeutics. This success is expected to strengthen Gelteq's position in the veterinary therapeutics landscape and facilitate strategic partnerships.

The Gross Law Firm has issued a shareholder alert for Zoetis Inc. (NYSE: ZTS), announcing a securities class action lawsuit. The complaint alleges that Zoetis made misleading statements and failed to disclose critical information regarding its products, including weakening prescription growth for Librela due to FDA safety warnings, loss of market share for Simparica Trio, and substantial market share loss for Apoquel and Cytopoint. Shareholders who purchased ZTS shares between January 14, 2025, and May 6, 2026, are encouraged to contact the law firm, with a lead plaintiff deadline of July 27, 2026.